Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Hansa Biopharma AB's Total Liabilities for the quarter that ended in Jun. 2026 was kr1,591.0 Mil. Hansa Biopharma AB's Total Assets for the quarter that ended in Jun. 2026 was kr1,070.8 Mil.
Therefore, Hansa Biopharma AB's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2026 was 1.49.
Hansa Biopharma AB (CHIX:HNSAs) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Hansa Biopharma AB Liabilities-to-Assets Related Terms
Hansa Biopharma AB Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Hansa Biopharma AB's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:HNSAS vs VRTX, REGN, RVMD: Liabilities-to-Assets Comparison
For the Biotechnology subindustry, Hansa Biopharma AB's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's Liabilities-to-Assets falls into.
Hansa Biopharma AB Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Hansa Biopharma AB's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB (CHIX:HNSAS) has a Liabilities-to-Assets of 1.49 as of Jun. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Liabilities-to-Assets too high?
Hansa Biopharma AB's current Liabilities-to-Assets is 1.49. Overall, Hansa Biopharma AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Liabilities-to-Assets compare to VRTX and REGN?
Hansa Biopharma AB's Liabilities-to-Assets of 1.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Liabilities-to-Assets is 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Hansa Biopharma AB (CHIX:HNSAS) has a current Liabilities-to-Assets of 1.49. The stock's GF Value™ is kr12.75, compared to a current price of kr25.64 — trading 101.1% above its estimated fair value. The current Liabilities-to-Assets is 1.49. Hansa Biopharma AB's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Hansa Biopharma AB (CHIX:HNSAS), the current Liabilities-to-Assets is 1.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (CHIX:HNSAS) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr25.64 is trading 101.1% above its estimated GF Value™ of kr12.75.
Key valuation signals for CHIX:HNSAS:
Liabilities-to-Assets: 1.49
GF Value™: kr12.75 vs. price of kr25.64 (101.1% above fair value)
No single metric tells the full story. See the CHIX:HNSAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
43GF Score
Get the complete analysis for CHIX:HNSAS
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:HNSAS has been successfully added to your 
